Search

Displaying results 4621 - 4630 of 10000 in total
  1. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)

  2. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  3. Drug

    Managlinat dialanetil

    go.drugbank.com/drugs/DB05518
    Investigational

    CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.

  4. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    It is being developed by CV Therapeutics, Inc. … Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

  5. Drug

    Cefaclor

    go.drugbank.com/drugs/DB00833
    ApprovedInvestigational

    Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

  6. Drug

    Procaterol

    go.drugbank.com/drugs/DB01366
    ApprovedWithdrawn

    It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

  7. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.

  8. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

  9. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551].

    Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-Carboxylate
  10. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational